LENSAR, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from LENSAR, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Growth Efficiency Ratio: Sales grew 65% in 3 years, but profit fell: $62 less profit per $100 of extra sales. Lower than 85% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-56.3×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 74% of Healthcare companies in United States.
Cash Locked Ratio
$16For every $100 of sales, $16 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $36 tied up three years earlier.
Less money tied up than 67% of Healthcare companies in United States.
Growth quality
Steadiness Ratio
3/3 · 1/3Sales grew in 3 of the last 3 years; profit grew in 1 of 3.
Steadier than 69% of Healthcare companies in United States.
Growth Efficiency Ratio
−$62Sales grew 65% in 3 years, but profit fell: $62 less profit per $100 of extra sales.
Lower than 85% of Healthcare companies in United States.
Asset Productivity Ratio
+65% / +28%In 3 years sales changed by +65% while total assets changed by +28%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
-19.9×Operating cash was negative last year, while some debt falls due within a year.
Lower than 54% of Healthcare companies in United States.
Cash Cushion Ratio
+21%Cash, after subtracting all debt, equals 21% of its market value (net cash).
Higher than 63% of Healthcare companies in United States.
Tangible Assets Ratio
93%Of every $100 the company owns, $93 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 65% of Healthcare companies in United States.
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (12)
LENSAR, Inc. owes $0.79 for every $1 it owns. LENSAR, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
33.4Investors pay $33.4 for every $1 of LENSAR, Inc.'s yearly profit, higher than 62% of Healthcare companies in United States.
P/B ratio
4.96The share price is 4.96 times LENSAR, Inc.'s book value per share, higher than 71% of Healthcare companies in United States.
Market cap
$74 MThe total market value of all of LENSAR, Inc.'s shares at today's price (share price × number of shares), smaller than 70% of Healthcare companies in United States. PosiCap size class: Micro Cap.
Net worth (book value)
$15 MWhat LENSAR, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$1.21Net worth divided by the number of shares. The share price of $6.02 is 5.0 times this, which is the P/B above.
Return on equity (ROE)
357.3%LENSAR, Inc. earned 357.3% on its shareholders' money over the last year, higher than almost all Healthcare companies in United States.
Owes vs Owns
0.79×LENSAR, Inc. owes $0.79 for every $1 it owns (moderate), higher than 77% of Healthcare companies in United States.
Dividend yield
NoneLENSAR, Inc. does not currently pay a dividend.
Revenue growth
+9%Revenue rose 9% in the year to Dec 2025, and grew 18% a year on average over 3 years.
Profit growth
LossLENSAR, Inc. made a loss in each of the last two years.
Profit margin
-58.7%LENSAR, Inc. lost $59 for every $100 of revenue.
Cash vs debt
Net cashLENSAR, Inc. held $15 M more cash than debt (net cash) at Dec 2025.
Questions
What is LENSAR, Inc.'s P/E ratio?
Investors pay $33.4 for every $1 of LENSAR, Inc.'s yearly profit, higher than 62% of Healthcare companies in United States.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For LENSAR, Inc.: $74 M ÷ $15 M (30 Jun 2026) = 5.0.
What is LENSAR, Inc.'s return on equity?
LENSAR, Inc. earned 357.3% on its shareholders' money over the last year, higher than almost all Healthcare companies in United States.
How much does LENSAR, Inc. owe compared with what it owns?
LENSAR, Inc. owes $0.79 for every $1 it owns (moderate), higher than 77% of Healthcare companies in United States.
Does LENSAR, Inc. pay a dividend?
No. LENSAR, Inc. does not currently pay a dividend.
Is LENSAR, Inc.'s revenue growing?
Revenue rose 9% in the year to Dec 2025, and grew 18% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.